Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?

Can J Psychiatry. 2021 Feb;66(2):185-194. doi: 10.1177/0706743720945525. Epub 2020 Sep 11.

Abstract

A position statement developed by the Canadian Psychiatric Association's (CPA) Research Committee and approved by the CPA's Board of Directors on May 13, 2020.

MeSH terms

  • Adult
  • Canada
  • Cannabinoids*
  • Humans
  • Mental Disorders* / drug therapy
  • Psychiatry*
  • Societies, Medical

Substances

  • Cannabinoids